Antiplatelet drugs are the treatment of choice for preventing recurrence of noncardioembolic ischaemic stroke, but numerous updates to clinical guidelines, most recently in 2011 in the USA, have made selection of the appropriate antiplatelet agent difficult. In their Review, Craig Williams and colleagues provide an overview of the evolving guidelines in the context of results from the many large clinical trials in this field.
- Bruce A. Warden
- Alana M. Willman
- Craig D. Williams
